Relay Therapeutics Inc (NASDAQ: RLAY) kicked off on Friday, up 3.49% from the previous trading day, before settling in for the closing price of $6.30. Over the past 52 weeks, RLAY has traded in a range of $5.70-$13.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 319.82%. While this was happening, its average annual earnings per share was recorded -1.28%. With a float of $120.03 million, this company’s outstanding shares have now reached $127.46 million.
The extent of productivity of a business whose workforce counts for 323 workers is very important to gauge.
Relay Therapeutics Inc (RLAY) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 9.58%, while institutional ownership is 72.39%. The most recent insider transaction that took place on Jun 05 ’24, was worth 144,377. In this transaction an insider of this company sold 20,450 shares at a rate of $7.06, taking the stock ownership to the 432,425 shares. Before that another transaction happened on Jun 04 ’24, when Company’s See remarks sold 40,595 for $6.64, making the entire transaction worth $269,551. This insider now owns 452,875 shares in total.
Relay Therapeutics Inc (RLAY) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -1.28% per share during the next fiscal year.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Take a look at Relay Therapeutics Inc’s (RLAY) current performance indicators. Last quarter, stock had a quick ratio of 20.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.64, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -2.85 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
The latest stats from [Relay Therapeutics Inc, RLAY] show that its last 5-days average volume of 1.29 million was superior to 1.22 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 20.39%. Additionally, its Average True Range was 0.53.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 15.02%, which indicates a significant decrease from 22.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.79% in the past 14 days, which was lower than the 67.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.77, while its 200-day Moving Average is $8.36. Now, the first resistance to watch is $6.71. This is followed by the second major resistance level at $6.91. The third major resistance level sits at $7.24. If the price goes on to break the first support level at $6.19, it is likely to go to the next support level at $5.86. Assuming the price breaks the second support level, the third support level stands at $5.66.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
The company with the Market Capitalisation of 865.46 million has total of 132,742K Shares Outstanding. Its annual sales at the moment are 25,550 K in contrast with the sum of -341,970 K annual income. Company’s last quarter sales were recorded 10,010 K and last quarter income was -81,390 K.
